Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2013

01-08-2013 | Epidemiology

Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study

Authors: Martha L. Slattery, Esther M. John, Mariana C. Stern, Jennifer Herrick, Abbie Lundgreen, Anna R. Giuliano, Lisa Hines, Kathy B. Baumgartner, Gabriela Torres-Mejia, Roger K. Wolff

Published in: Breast Cancer Research and Treatment | Issue 3/2013

Login to get access

Abstract

Growth factors (GF) stimulate cell proliferation through binding to cell membrane receptors and are thought to be involved in cancer risk and survival. We examined how genetic variation in epidermal growth factor (EGF), neuregulin 2 (NRG2), ERBB2 (HER2/neu), fibroblast growth factors 1 and 2 (FGF1 and FGF2) and its receptor 2 (FGFR2), and platelet-derived growth factor B (PDGFB) independently and collectively influence breast cancer risk and survival. We analyzed data from the Breast Cancer Health Disparities Study which includes Hispanic (2,111 cases, 2,597 controls) and non-Hispanic white (1,481 cases, 1,586 controls) women. Adaptive rank-truncated product (ARTP) analysis was conducted to determine gene significance. Odds ratios (OR) and 95 % confidence intervals were obtained from conditional logistic regression models to estimate breast cancer risk and Cox proportional hazard models were used to estimate hazard ratios (HR) of dying from breast cancer. We assessed Native American (NA) ancestry using 104 ancestry informative markers. We observed few significant associations with breast cancer risk overall or by menopausal status other than for FGFR2 rs2981582. This SNP was significantly associated with ER+/PR+ (OR 1.66, 95 % CI 1.37–2.00) and ER+/PR− (OR 1.54, 95 % CI 1.03–2.31) tumors. Multiple SNPs in FGF1, FGF2, and NRG2 significantly interacted with multiple SNPs in EGFR, ERBB2, FGFR2, and PDGFB, suggesting that breast cancer risk is dependent on the collective effects of genetic variants in other GFs. Both FGF1 and ERBB2 significantly influenced overall survival, especially among women with low levels of NA ancestry (P ARTP = 0.007 and 0.003, respectively). Our findings suggest that genetic variants in growth factors signaling appear to influence breast cancer risk through their combined effects. Genetic variation in ERBB2 and FGF1 appear to be associated with survival after diagnosis with breast cancer.
Appendix
Available only for authorised users
Literature
1.
Goustin AS, Leof EB, Shipley GD, Moses HL (1986) Growth factors and cancer. Cancer Res 46:1015–1029PubMed
2.
Auvinen P, Lipponen P, Johansson R, Syrjanen K (1995) Prognostic significance of TGF-beta 1 and TGF-beta 2 expressions in female breast cancer. Anticancer Res 15:2627–2631PubMed
3.
Mu L, Katsaros D, Lu L, Preti M, Durando A et al (2008) TGF-beta1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. Br J Cancer 99:1357–1363PubMedCrossRef
4.
Beeghly-Fadiel A, Shu XO, Lu W, Long J, Cai Q et al (2011) Genetic variation in VEGF family genes and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study. Cancer Epidemiol Biomarkers Prev 20:33–41PubMedCrossRef
5.
Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A et al (2012) The single-nucleotide polymorphisms +936 C/T VEGF and −710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Breast Cancer Res Treat 133:769–778PubMedCrossRef
6.
Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M et al (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39:870–874PubMedCrossRef
7.
Barnholtz-Sloan JS, Shetty PB, Guan X, Nyante SJ, Luo J et al (2010) FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women. Carcinogenesis 31:1417–1423PubMedCrossRef
8.
Jara L, Gonzalez-Hormazabal P, Cerceno K, Di Capua GA, Reyes JM et al (2013) Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population. Breast Cancer Res Treat 137:559–569PubMedCrossRef
9.
Chen F, Lv M, Xue Y, Zhou J, Hu F et al (2012) Genetic variants of fibroblast growth factor receptor 2 (FGFR2) are associated with breast cancer risk in Chinese women of the Han nationality. Immunogenetics 64:71–76PubMedCrossRef
10.
Jia C, Cai Y, Ma Y, Fu D (2010) Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer. Breast Cancer Res Treat 124:521–528PubMedCrossRef
11.
Fejerman L, Stern MC, Ziv E, John EM, Torres-Mejia G et al (2013) Genetic ancestry modifies the association between genetic risk variants and breast cancer risk among Hispanic and non-Hispanic white women. Carcinogenesis
12.
Watnick RS (2012) The role of the tumor microenvironment in regulating angiogenesis. Cold Spring Harb Perspect Med 2:a006676PubMedCrossRef
13.
Soufla G, Sifakis S, Spandidos DA (2008) FGF2 transcript levels are positively correlated with EGF and IGF-1 in the malignant endometrium. Cancer Lett 259:146–155PubMedCrossRef
14.
Olsen DA, Bechmann T, Ostergaard B, Wamberg PA, Jakobsen EH et al (2012) Increased concentrations of growth factors and activation of the EGFR system in breast cancer. Clin Chem Lab Med 50:1809–1818PubMedCrossRef
15.
Navolanic PM, Steelman LS, McCubrey JA (2003) EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol 22:237–252PubMed
16.
Chrysogelos SA, Dickson RB (1994) EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res Treat 29:29–40PubMedCrossRef
17.
Wang Y, Tian T, Hu Z, Tang J, Wang S et al (2008) EGF promoter SNPs, plasma EGF levels and risk of breast cancer in Chinese women. Breast Cancer Res Treat 111:321–327PubMedCrossRef
18.
Henjes F, Bender C, von der Heyde S, Braun L, Mannsperger HA et al (2012) Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis 1:e16PubMedCrossRef
19.
Idirisinghe PK, Thike AA, Cheok PY, Tse GM, Lui PC et al (2010) Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol 133:416–429PubMedCrossRef
20.
Dahabreh IJ, Murray S (2011) Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: a systematic review and meta-analysis. Cancer Epidemiol 35:503–509PubMedCrossRef
21.
Goldsmith KT, Gammon RB, Garver RI Jr (1991) Modulation of bFGF in lung fibroblasts by TGF-beta and PDGF. Am J Physiol 261:L378–L385PubMed
22.
Brogi E, Wu T, Namiki A, Isner JM (1994) Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 90:649–652PubMedCrossRef
23.
Slattery ML, John EM, Torres-Mejia G, Lundgreen A, Herrick JS et al (2012) Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed population. Carcinogenesis 33:1512–1521PubMedCrossRef
24.
Slattery ML, Sweeney C, Edwards S, Herrick J, Baumgartner K et al (2007) Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Res Treat 102:85–101PubMedCrossRef
25.
John EM, Horn-Ross PL, Koo J (2003) Lifetime physical activity and breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. Cancer Epidemiol Biomarkers Prev 12:1143–1152PubMed
26.
John EM, Phipps AI, Davis A, Koo J (2005) Migration history, acculturation, and breast cancer risk in Hispanic women. Cancer Epidemiol Biomarkers Prev 14:2905–2913PubMedCrossRef
27.
Falush D, Stephens M, Pritchard JK (2003) Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 164:1567–1587PubMed
28.
Pritchard JK, Stephens M, Donnelly P (2000) Inference of population structure using multilocus genotype data. Genetics 155:945–959PubMed
29.
Nyholt DR (2004) A simple correction for multiple testing of single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Human Genetics 74:765–769
30.
Li J, Ji L (2005) Adjusting multiple testing in multilocus analysis using the eigenvalues of a correlation matrix. Heredity 95:221–227
31.
Yu K, Li Q, Bergen AW, Pfeiffer RM, Rosenberg PS et al (2009) Pathway analysis by adaptive combination of P-values. Genet Epidemiol 33:700–709PubMedCrossRef
32.
Kai Yu OL, Wheeler W (2011) ARTP gene and pathway p-values computed using the Adaptive Rank Truncated Product. 2.0.0 ed. pp. R package
33.
Cen YL, Qi ML, Li HG, Su Y, Chen LJ et al (2012) Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status. Mol Carcinog. doi:10.​1002/​mc.​21979
Metadata
Title
Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study
Authors
Martha L. Slattery
Esther M. John
Mariana C. Stern
Jennifer Herrick
Abbie Lundgreen
Anna R. Giuliano
Lisa Hines
Kathy B. Baumgartner
Gabriela Torres-Mejia
Roger K. Wolff
Publication date
01-08-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2644-5

Other articles of this Issue 3/2013

Breast Cancer Research and Treatment 3/2013 Go to the issue

Epidemiology

Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women

Review

Everolimus: side effect profile and management of toxicities in breast cancer

Clinical Trial

Surgical impact of preoperative breast MRI in women below 40 years of age

Epidemiology

Clinical outcomes following nipple–areola-sparing mastectomy with immediate implant-based breast reconstruction: a 12-year experience with an analysis of patient and breast-related factors for complications

Epidemiology

Impact of primary local treatment on the development of distant metastases or death through locoregional recurrence in young breast cancer patients

Epidemiology

Hospital and surgeon caseload are associated with risk of re-operation following breast-conserving surgery
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits